Clinical Trial Detail

NCT ID NCT02032823
Title Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer (OlympiA)
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements yes
Sponsors AstraZeneca
Indications

Her2-receptor negative breast cancer

Therapies

Olaparib

Age Groups: adult senior

Additional content available in CKB BOOST